help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ricort, J.-M.
Right arrow Articles by Binoux, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricort, J.-M.
Right arrow Articles by Binoux, M.
Endocrinology Vol. 142, No. 1 108-113
Copyright © 2001 by The Endocrine Society


ARTICLES

Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits Type 1 IGF Receptor Activation Independently of Its IGF Binding Affinity1

Jean-Marc Ricort2 and Michel Binoux

Institut National de la Santé et de la Recherche Médicale, Unité 515, Croissance, Différenciation et Processus tumoraux, Hôpital Saint-Antoine, Paris, France

Address all correspondence and requests for reprints to: J-M Ricort, INSERM U.515, Hôpital Saint-Antoine, 184 rue du Faubourg Saint-Antoine, 75571 Paris CEDEX 12, France. E-mail. ricort{at}st-antoine.inserm.fr

Insulin-like growth factor binding proteins (IGFBPs) regulate the cellular actions of the IGFs owing to their strong affinities, which are equal to or stronger than the affinity of the type 1 IGF receptor (IGF-IR), the mediator of IGF signal transduction. We recently found that IGFBP-3 modulates IGF-I binding to its receptor via a different mechanism possibly involving conformational alteration of the receptor. We have now investigated the effects of IGFBP-3 on the initial steps in the IGF signaling pathway. MCF-7 breast carcinoma cells were preincubated with increasing concentrations of IGFBP-3 and then stimulated with IGF-I, des(1–3)IGF-I, or [Q3A4Y15L16]-IGF-I, the latter two being IGF-I analogs with intact affinity for the type 1 IGF receptor, but weak or virtually no affinity for IGFBPs. Stimulation of autophosphorylation of the receptor and its tyrosine kinase activity was dose-dependently depressed. At 2.5 nM, IGFBP-3 provoked more than 50% inhibition of the stimulation induced by 3 nM des(1–3)IGF-1 and, at 10 nM, more than 80% inhibition. Similar results were obtained with [Q3A4Y15L16]-IGF-I. Cross-linking experiments using iodinated or unlabeled IGFBP-3 and anti-IGF-IR antibodies indicated that the inhibitory effects do not involve direct interaction between IGFBP-3 and IGF-IR. The inhibition appeared to be specific to IGFBP-3, because IGFBP-1 and IGFBP-5 at 10 nM had no significant effect. Also, inhibition was restricted to the IGF receptor, because IGFBP-3 failed to inhibit the tyrosine kinase activity of the insulin receptor stimulated by physiological concentrations of insulin. Our results provide the first demonstration that IGFBP-3 can specifically modulate the IGF-I signaling pathway independently of its IGF-I-binding ability. They also reveal a regulatory mechanism specific to the type 1 IGF receptor, with no effect on insulin receptor activation.




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. Jerome, N. Alami, S. Belanger, V. Page, Q. Yu, J. Paterson, L. Shiry, M. Pegram, and B. Leyland-Jones
Recombinant Human Insulin-like Growth Factor Binding Protein 3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2-Overexpressing Breast Tumors and Potentiates Herceptin Activity In vivo.
Cancer Res., July 15, 2006; 66(14): 7245 - 7252.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
M. R. Hathaway, W. R. Dayton, M. E. White, and M. S. Pampusch
Effects of antimicrobials and weaning on porcine serum insulin-like growth factor binding protein levels
J Anim Sci, June 1, 2003; 81(6): 1456 - 1463.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
E. Marshman, K. A. Green, D. J. Flint, A. White, C. H. Streuli, and M. Westwood
Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells
J. Cell Sci., February 15, 2003; 116(4): 675 - 682.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. M. Firth and R. C. Baxter
Cellular Actions of the Insulin-Like Growth Factor Binding Proteins
Endocr. Rev., December 1, 2002; 23(6): 824 - 854.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-M. Ricort and M. Binoux
Insulin-like Growth Factor-binding Protein-3 Activates a Phosphotyrosine Phosphatase. EFFECTS ON THE INSULIN-LIKE GROWTH FACTOR SIGNALING PATHWAY
J. Biol. Chem., May 24, 2002; 277(22): 19448 - 19454.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Hong, G. Zhang, F. Dong, and M. M. Rechler
Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells
J. Biol. Chem., March 15, 2002; 277(12): 10489 - 10497.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. K. Buckway, E. M. Wilson, M. Ahlsen, P. Bang, Y. Oh, and R. G. Rosenfeld
Mutation of Three Critical Amino Acids of the N-Terminal Domain of IGF-Binding Protein-3 Essential for High Affinity IGF Binding
J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4943 - 4950.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society